Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

Current Hepatitis Reports

, Volume 11, Issue 3, pp 181-187

First online:

NS5A Inhibitors

  • Christopher O’BrienAffiliated withMiller School of Medicine, University of MiamiCenter for Liver Diseases Email author 
  • , Nicholas AgrestiAffiliated withMiller School of Medicine, University of Miami

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The structure of this protein consists of three separate domains that are still under investigation as far as their function. Information, however, suggests that the NS5A acts within the context of a multi-protein complex. There has now been rapid and extensive the investigation of the use of a multitude of NS5A inhibitors from a variety of pharmaceutical companies. The activities and results of these various inhibitors in both preclinical as well as their clinical trials are examined during the course of this review.


HCV Hepatitis C NS5A DAA Direct acting antivirals Daclatasvir BMS-790052 ABT-267 ACH-2928 ACH-3102 EDP-239 GS-5885 IDX719 ITMN-9959 PPI-461 PPI-688 Mericitabine Tegobuvir Danoprevir